SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Healthcare ITIn Vitro DiagnosticsDrug DiscoveryArtificial IntelligenceAI Drug DiscoveryDiagnostics AI

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2161904

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2161904

Agentic AI in Pharmaceuticals Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

Introduction

Agentic artificial intelligence is beginning to change how pharmaceutical companies discover, develop, manufacture and monitor medicines. Unlike conventional tools that answer a single query, AI agents can plan and carry out multi-step tasks, such as drafting regulatory documents, triaging safety cases or coordinating clinical trial workflows, with human oversight at key points. In 2026, the market is valued at US$1.3 Bn and is projected to reach US$13 Bn by 2033, registering a CAGR of 38.95%. This exceptional pace reflects a technology moving from pilots into production across research and operations. Pharmaceutical work is heavy with documentation, rules and repeatable processes, which makes it well suited to automation that can read, reason and act across systems. Companies are under strong pressure to improve research and development productivity as patents expire and trial costs rise. At the same time, regulators are clarifying expectations for AI use, and validation frameworks are evolving, allowing more organisations to deploy agents in regulated environments with confidence.

Market Insights

The market is segmented by component, application, deployment model and end user. Components include agent platforms and orchestration software, domain-specific agent applications, implementation and validation services, and managed and support services. Applications cover drug discovery and preclinical research, clinical development and trial operations, regulatory affairs and medical writing, pharmacovigilance and drug safety, manufacturing and quality operations, and commercial and medical affairs. Deployment options include on-premises, private cloud, public cloud GxP-qualified software as a service, and hybrid models. End users comprise large pharmaceutical companies, emerging biotechnology firms, contract research organisations and contract development and manufacturing organisations. Between 2020 and 2025, the market grew at an estimated 62.0% CAGR, though from a negligible base. Domain-specific agent applications are the fastest-growing component at 43.5% CAGR, as buyers favour tools built for specific pharmaceutical tasks. Regulatory affairs and medical writing leads application growth at 44.8% CAGR, and public cloud GxP-qualified SaaS is the fastest deployment model at 43.8% CAGR, signalling growing comfort with validated cloud delivery.

Drivers

The first major driver is the document-heavy nature of regulatory, safety and clinical trial workflows, which are well suited to multi-step agent automation. This carries high impact over the medium term. Preparing submissions, processing adverse event reports and managing trial documentation involve large volumes of structured and unstructured text, repeated checks and handoffs between teams. Agents can take on much of this work, cutting cycle times and freeing specialists for judgement-based tasks. The second driver is pressure on research and development productivity from patent expiries and rising trial costs, a high-impact force over the long term. As revenue from established products declines, companies need to bring new medicines forward faster and at lower cost. Restraints are notable. GxP computerised system validation and data integrity obligations are difficult to apply to non-deterministic agents, creating a high-impact, long-term hurdle. Regulatory acceptability and accountability for autonomous agent decisions also remain unsettled, which slows deployment in the most sensitive processes and keeps human review firmly in the loop.

Business Opportunity

Outsourced pharmacovigilance case processing offers a strong opportunity as it shifts toward agent-delivered services. Safety teams handle growing volumes of adverse event reports that must be collected, coded, assessed and submitted within strict timelines. Agents can carry out much of this workflow under human supervision, allowing service providers to offer case processing priced per case rather than per staff hour. This creates a scalable service pool that benefits both providers and pharmaceutical clients seeking predictable costs and consistent quality. A second opportunity is emerging for contract research and contract manufacturing organisations that build agent-enabled delivery models. By embedding agents into trial management, documentation, quality review and batch record processes, these providers can deliver faster and more consistent outcomes. This opens the door to outcome-based pricing, where fees are tied to results such as milestones achieved rather than hours worked. Providers that move early can differentiate their offerings, deepen client relationships and capture a larger share of outsourced pharmaceutical spending over the forecast period.

Region Analysis

North America leads the market with a 48.0% share in 2026, supported by a concentration of large pharmaceutical companies, strong research and development spending, a deep technology vendor base and early regulatory guidance on AI use in drug development. Europe holds 25%, where adoption is shaped by the phased obligations of the EU AI Act alongside established GxP and data protection requirements. Asia Pacific accounts for 20.5% and is the fastest-growing region at 45.0% CAGR, driven by expanding biopharmaceutical research, growing contract research and manufacturing capacity, and rapid adoption of cloud-based tools. Latin America represents 3.5%, with uptake building through clinical trial activity and multinational operations. The Middle East and Africa holds 3.0%, where investment in life sciences and digital health is at an earlier stage. Across these five regions, regulatory clarity, the availability of validated cloud infrastructure and the presence of outsourced service providers will shape how quickly pharmaceutical organisations move agentic AI from pilots into routine operations.

Key Players

  • Microsoft Corporation
  • NVIDIA Corporation
  • Veeva Systems Inc.
  • International Business Machines Corporation
  • Certara, Inc.
  • Salesforce, Inc.
  • Oracle Corporation
  • SAP SE
  • Dassault Systemes SE
  • Schrodinger, Inc.

Segmentation

By Component:

  • Agent Platforms and Orchestration Software
  • Domain-Specific Agent Applications
  • Implementation and Validation Services
  • Managed and Support Services

By Application:

  • Drug Discovery and Preclinical Research
  • Clinical Development and Trial Operations
  • Regulatory Affairs and Medical Writing
  • Pharmacovigilance and Drug Safety
  • Manufacturing and Quality Operations
  • Commercial and Medical Affairs

By Deployment Model:

  • On-Premises
  • Private Cloud
  • Public Cloud GxP-Qualified SaaS
  • Hybrid

By End User:

  • Large Pharmaceutical Companies
  • Emerging Biotechnology Companies
  • Contract Research Organizations
  • Contract Development and Manufacturing Organizations

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Agentic AI in Pharmaceuticals Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Agentic AI in Pharmaceuticals Market Outlook, 2020-2033

  • 3.1. Global Agentic AI in Pharmaceuticals Market Outlook, by Component, Value (US$ Bn), 2020-2033
    • 3.1.1. Agent Platforms and Orchestration Software
    • 3.1.2. Domain-Specific Agent Applications
    • 3.1.3. Implementation and Validation Services
    • 3.1.4. Managed and Support Services
  • 3.2. Global Agentic AI in Pharmaceuticals Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 3.2.1. Drug Discovery and Preclinical Research
    • 3.2.2. Clinical Development and Trial Operations
    • 3.2.3. Regulatory Affairs and Medical Writing
    • 3.2.4. Pharmacovigilance and Drug Safety
    • 3.2.5. Manufacturing and Quality Operations
    • 3.2.6. Commercial and Medical Affairs
  • 3.3. Global Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, Value (US$ Bn), 2020-2033
    • 3.3.1. On-Premises
    • 3.3.2. Private Cloud
    • 3.3.3. Public Cloud GxP-Qualified SaaS
    • 3.3.4. Hybrid
  • 3.4. Global Agentic AI in Pharmaceuticals Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.4.1. Large Pharmaceutical Companies
    • 3.4.2. Emerging Biotechnology Companies
    • 3.4.3. Contract Research Organizations
    • 3.4.4. Contract Development and Manufacturing Organizations
  • 3.5. Global Agentic AI in Pharmaceuticals Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Agentic AI in Pharmaceuticals Market Outlook, 2020-2033

  • 4.1. North America Agentic AI in Pharmaceuticals Market Outlook, by Component, Value (US$ Bn), 2020-2033
    • 4.1.1. Agent Platforms and Orchestration Software
    • 4.1.2. Domain-Specific Agent Applications
    • 4.1.3. Implementation and Validation Services
    • 4.1.4. Managed and Support Services
  • 4.2. North America Agentic AI in Pharmaceuticals Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 4.2.1. Drug Discovery and Preclinical Research
    • 4.2.2. Clinical Development and Trial Operations
    • 4.2.3. Regulatory Affairs and Medical Writing
    • 4.2.4. Pharmacovigilance and Drug Safety
    • 4.2.5. Manufacturing and Quality Operations
    • 4.2.6. Commercial and Medical Affairs
  • 4.3. North America Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, Value (US$ Bn), 2020-2033
    • 4.3.1. On-Premises
    • 4.3.2. Private Cloud
    • 4.3.3. Public Cloud GxP-Qualified SaaS
    • 4.3.4. Hybrid
  • 4.4. North America Agentic AI in Pharmaceuticals Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.4.1. Large Pharmaceutical Companies
    • 4.4.2. Emerging Biotechnology Companies
    • 4.4.3. Contract Research Organizations
    • 4.4.4. Contract Development and Manufacturing Organizations
  • 4.5. North America Agentic AI in Pharmaceuticals Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.5.1. U.S. Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 4.5.2. U.S. Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 4.5.3. U.S. Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 4.5.4. U.S. Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 4.5.5. Canada Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 4.5.6. Canada Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 4.5.7. Canada Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 4.5.8. Canada Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Agentic AI in Pharmaceuticals Market Outlook, 2020-2033

  • 5.1. Europe Agentic AI in Pharmaceuticals Market Outlook, by Component, Value (US$ Bn), 2020-2033
    • 5.1.1. Agent Platforms and Orchestration Software
    • 5.1.2. Domain-Specific Agent Applications
    • 5.1.3. Implementation and Validation Services
    • 5.1.4. Managed and Support Services
  • 5.2. Europe Agentic AI in Pharmaceuticals Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 5.2.1. Drug Discovery and Preclinical Research
    • 5.2.2. Clinical Development and Trial Operations
    • 5.2.3. Regulatory Affairs and Medical Writing
    • 5.2.4. Pharmacovigilance and Drug Safety
    • 5.2.5. Manufacturing and Quality Operations
    • 5.2.6. Commercial and Medical Affairs
  • 5.3. Europe Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, Value (US$ Bn), 2020-2033
    • 5.3.1. On-Premises
    • 5.3.2. Private Cloud
    • 5.3.3. Public Cloud GxP-Qualified SaaS
    • 5.3.4. Hybrid
  • 5.4. Europe Agentic AI in Pharmaceuticals Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.4.1. Large Pharmaceutical Companies
    • 5.4.2. Emerging Biotechnology Companies
    • 5.4.3. Contract Research Organizations
    • 5.4.4. Contract Development and Manufacturing Organizations
  • 5.5. Europe Agentic AI in Pharmaceuticals Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.5.1. Germany Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.2. Germany Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.3. Germany Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.4. Germany Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 5.5.5. Italy Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.6. Italy Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.7. Italy Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.8. Italy Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 5.5.9. France Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.10. France Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.11. France Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.12. France Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 5.5.13. U.K. Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.14. U.K. Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.15. U.K. Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.16. U.K. Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 5.5.17. Spain Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.18. Spain Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.19. Spain Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.20. Spain Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 5.5.21. Russia Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.22. Russia Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.23. Russia Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.24. Russia Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 5.5.25. Rest of Europe Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 5.5.26. Rest of Europe Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 5.5.27. Rest of Europe Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 5.5.28. Rest of Europe Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Agentic AI in Pharmaceuticals Market Outlook, 2020-2033

  • 6.1. Asia Pacific Agentic AI in Pharmaceuticals Market Outlook, by Component, Value (US$ Bn), 2020-2033
    • 6.1.1. Agent Platforms and Orchestration Software
    • 6.1.2. Domain-Specific Agent Applications
    • 6.1.3. Implementation and Validation Services
    • 6.1.4. Managed and Support Services
  • 6.2. Asia Pacific Agentic AI in Pharmaceuticals Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 6.2.1. Drug Discovery and Preclinical Research
    • 6.2.2. Clinical Development and Trial Operations
    • 6.2.3. Regulatory Affairs and Medical Writing
    • 6.2.4. Pharmacovigilance and Drug Safety
    • 6.2.5. Manufacturing and Quality Operations
    • 6.2.6. Commercial and Medical Affairs
  • 6.3. Asia Pacific Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, Value (US$ Bn), 2020-2033
    • 6.3.1. On-Premises
    • 6.3.2. Private Cloud
    • 6.3.3. Public Cloud GxP-Qualified SaaS
    • 6.3.4. Hybrid
  • 6.4. Asia Pacific Agentic AI in Pharmaceuticals Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.4.1. Large Pharmaceutical Companies
    • 6.4.2. Emerging Biotechnology Companies
    • 6.4.3. Contract Research Organizations
    • 6.4.4. Contract Development and Manufacturing Organizations
  • 6.5. Asia Pacific Agentic AI in Pharmaceuticals Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.5.1. China Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 6.5.2. China Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 6.5.3. China Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 6.5.4. China Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 6.5.5. Japan Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 6.5.6. Japan Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 6.5.7. Japan Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 6.5.8. Japan Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 6.5.9. South Korea Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 6.5.10. South Korea Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 6.5.11. South Korea Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 6.5.12. South Korea Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 6.5.13. India Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 6.5.14. India Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 6.5.15. India Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 6.5.16. India Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 6.5.17. Southeast Asia Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 6.5.18. Southeast Asia Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 6.5.19. Southeast Asia Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 6.5.20. Southeast Asia Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 6.5.21. Rest of SAO Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 6.5.22. Rest of SAO Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 6.5.23. Rest of SAO Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 6.5.24. Rest of SAO Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Agentic AI in Pharmaceuticals Market Outlook, 2020-2033

  • 7.1. Latin America Agentic AI in Pharmaceuticals Market Outlook, by Component, Value (US$ Bn), 2020-2033
    • 7.1.1. Agent Platforms and Orchestration Software
    • 7.1.2. Domain-Specific Agent Applications
    • 7.1.3. Implementation and Validation Services
    • 7.1.4. Managed and Support Services
  • 7.2. Latin America Agentic AI in Pharmaceuticals Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 7.2.1. Drug Discovery and Preclinical Research
    • 7.2.2. Clinical Development and Trial Operations
    • 7.2.3. Regulatory Affairs and Medical Writing
    • 7.2.4. Pharmacovigilance and Drug Safety
    • 7.2.5. Manufacturing and Quality Operations
    • 7.2.6. Commercial and Medical Affairs
  • 7.3. Latin America Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, Value (US$ Bn), 2020-2033
    • 7.3.1. On-Premises
    • 7.3.2. Private Cloud
    • 7.3.3. Public Cloud GxP-Qualified SaaS
    • 7.3.4. Hybrid
  • 7.4. Latin America Agentic AI in Pharmaceuticals Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.4.1. Large Pharmaceutical Companies
    • 7.4.2. Emerging Biotechnology Companies
    • 7.4.3. Contract Research Organizations
    • 7.4.4. Contract Development and Manufacturing Organizations
  • 7.5. Latin America Agentic AI in Pharmaceuticals Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.5.1. Brazil Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 7.5.2. Brazil Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 7.5.3. Brazil Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 7.5.4. Brazil Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 7.5.5. Mexico Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 7.5.6. Mexico Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 7.5.7. Mexico Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 7.5.8. Mexico Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 7.5.9. Argentina Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 7.5.10. Argentina Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 7.5.11. Argentina Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 7.5.12. Argentina Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 7.5.13. Rest of LATAM Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 7.5.14. Rest of LATAM Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 7.5.15. Rest of LATAM Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 7.5.16. Rest of LATAM Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Agentic AI in Pharmaceuticals Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Agentic AI in Pharmaceuticals Market Outlook, by Component, Value (US$ Bn), 2020-2033
    • 8.1.1. Agent Platforms and Orchestration Software
    • 8.1.2. Domain-Specific Agent Applications
    • 8.1.3. Implementation and Validation Services
    • 8.1.4. Managed and Support Services
  • 8.2. Middle East & Africa Agentic AI in Pharmaceuticals Market Outlook, by Application, Value (US$ Bn), 2020-2033
    • 8.2.1. Drug Discovery and Preclinical Research
    • 8.2.2. Clinical Development and Trial Operations
    • 8.2.3. Regulatory Affairs and Medical Writing
    • 8.2.4. Pharmacovigilance and Drug Safety
    • 8.2.5. Manufacturing and Quality Operations
    • 8.2.6. Commercial and Medical Affairs
  • 8.3. Middle East & Africa Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, Value (US$ Bn), 2020-2033
    • 8.3.1. On-Premises
    • 8.3.2. Private Cloud
    • 8.3.3. Public Cloud GxP-Qualified SaaS
    • 8.3.4. Hybrid
  • 8.4. Middle East & Africa Agentic AI in Pharmaceuticals Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.4.1. Large Pharmaceutical Companies
    • 8.4.2. Emerging Biotechnology Companies
    • 8.4.3. Contract Research Organizations
    • 8.4.4. Contract Development and Manufacturing Organizations
  • 8.5. Middle East & Africa Agentic AI in Pharmaceuticals Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.5.1. GCC Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 8.5.2. GCC Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 8.5.3. GCC Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 8.5.4. GCC Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 8.5.5. South Africa Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 8.5.6. South Africa Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 8.5.7. South Africa Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 8.5.8. South Africa Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 8.5.9. Egypt Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 8.5.10. Egypt Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 8.5.11. Egypt Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 8.5.12. Egypt Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 8.5.13. Nigeria Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 8.5.14. Nigeria Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 8.5.15. Nigeria Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 8.5.16. Nigeria Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
    • 8.5.17. Rest of Middle East Agentic AI in Pharmaceuticals Market Outlook, by Component, 2020-2033
    • 8.5.18. Rest of Middle East Agentic AI in Pharmaceuticals Market Outlook, by Application, 2020-2033
    • 8.5.19. Rest of Middle East Agentic AI in Pharmaceuticals Market Outlook, by Deployment Model, 2020-2033
    • 8.5.20. Rest of Middle East Agentic AI in Pharmaceuticals Market Outlook, by End User, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Microsoft Corporation
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. NVIDIA Corporation
    • 9.4.3. Veeva Systems Inc.
    • 9.4.4. International Business Machines Corporation
    • 9.4.5. Certara, Inc.
    • 9.4.6. Salesforce, Inc.
    • 9.4.7. Oracle Corporation
    • 9.4.8. SAP SE
    • 9.4.9. Dassault Systemes SE
    • 9.4.10. Schrodinger, Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!